Emerging therapies, including HDAC inhibitors, proteasome inhibitors, and immunotherapies, show promise but require further study to address tumor heterogeneity and optimize efficacy.<h4>Conclusion</h4>This case underscores the critical role of early diagnosis and effective multidisciplinary management in relapsed T-LBL with skin involvement. The gene discussed is HDAC9; the disease is neoplasm.